Insulin for all: treatment activism and the global diabetes crisis

Lancet. 2019 May 25;393(10186):2116-2117. doi: 10.1016/S0140-6736(19)31090-6.

Authors

Jing Luo¹, Gregg Gonsalves², Jeremy Greene³

Affiliations

¹ Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02120, USA. Electronic address: jluo1@bwh.harvard.edu.
² Department of Epidemiology (Microbial Diseases), Yale School of Public Health, New Haven, CT, USA.
³ Departments of Medicine and History of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

PMID: 31226040
DOI: 10.1016/S0140-6736(19)31090-6

No abstract available

MeSH terms

Diabetes Mellitus, Type 1 / drug therapy*
Diabetes Mellitus, Type 2 / drug therapy*
Drug Industry
Drugs, Generic / supply & distribution
Global Health
Healthcare Disparities
Humans
Hypoglycemic Agents / supply & distribution
Hypoglycemic Agents / therapeutic use*
Insulin / supply & distribution
Insulin / therapeutic use*

Substances

Drugs, Generic
Hypoglycemic Agents
Insulin